Executive Director, Head of Bioanalytical Sciences
-
Healthcare
Job Description & How to Apply Below
We are developing potentially best-in-class therapies for patients living with severe autoimmune diseases. Our lead antibody, claseprubart (DNTH
103), is purposefully engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein that drives disease pathology – enabling less frequent and more convenient self-administered subcutaneous injections. Our second clinical candidate, DNTH
212 is a first and potentially best in class, bifunctional inhibitor that targets clinically validated and complementary disease modifying mechanisms, Type 1 IFN suppression and B cell modulation – enabling potential for improved clinical outcomes and patient friendly convenient, self-administered subcutaneous injections. Our newest candidate, DNTH
312, is an internally developed, investigational, first-in-class, next-generation bifunctional fusion protein combining claseprubart and TACI to target potent inhibition of aC1s and BAFF/APRIL. DNTH
312 aims to be Phase 1 ready by year end 2027. To learn more, please visit and follow us on Linked In.
We are developing potentially best-in-class therapies for patients living with severe autoimmune diseases. Our lead antibody, claseprubart (DNTH
103), is purposefully engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein that drives disease pathology – enabling less frequent and more convenient self-administered subcutaneous injections. Our second clinical candidate, DNTH
212 is a first and potentially best in class, bifunctional inhibitor that targets clinically validated and complementary disease modifying mechanisms, Type 1 IFN suppression and B cell modulation – enabling potential for improved clinical outcomes and patient friendly convenient, self-administered subcutaneous injections. Our newest candidate, DNTH
312, is an internally developed, investigational, first-in-class, next-generation bifunctional fusion protein combining claseprubart and TACI to target potent inhibition of aC1s and BAFF/APRIL. DNTH
312 aims to be Phase 1 ready by year end 2027. To learn more, please visit and follow us on Linked In.
The Executive Director, Head of Bioanalytical Sciences will lead the company's bioanalytical strategy and execution across research, translational, and clinical development. Reporting to the Senior Vice President, Clinical and Translational Development, this individual will serve as the senior scientific authority for bioanalytical and biomarker assays and a key partner to program teams, senior leadership, Regulatory, Quality, Clinical Pharmacology, and external collaborators.
The successful candidate will combine deep assay expertise with strong people leadership, executive communication, and operational judgment. The role is accountable for building a scalable function, ensuring assay readiness and data quality, and managing resources across internal headcount, CROs, specialty laboratories, and consultants.
We are building a culture of individuals who hold our core principles at the center of our operations, with the goal to elevate the care of our patients' lives. We are open to you working remotely.
Key Responsibilities- Define and execute the company-wide bioanalytical strategy, operating model, standards, and capability roadmap in alignment with portfolio priorities and development plans.
- Lead bioanalytical support across research, translational, and clinical programs, including PK, pharmacodynamic, immunogenicity, neutralizing antibody, biomarker, and other program-specific assays.
- Provide scientific oversight for assay strategy, platform selection, critical reagents, method development, qualification and validation,…
(If this job is in fact in your jurisdiction, then you may be using a Proxy or VPN to access this site, and to progress further, you should change your connectivity to another mobile device or PC).
View / Apply for Jobs
Matching My Jurisdiction